|
Clinical Features
|
n (%)
|
|---|
|
Age (y)
|
|
62.4 ± 9
|
–
|
|
Range (42–88)
|
–
|
|
Sex
|
|
F
|
32 (23.9%)
|
|
M
|
102 (76.1%)
|
|
Grade of differentiation
|
|
Highly differentiated (G1)
|
12 (9.0%)
|
|
Moderately differentiated(G2)
|
95 (70.9%)
|
|
Poorly differentiated(G3)
|
22 (16.4%)
|
|
Undifferentiated (G4)
|
5 (3.7%)
|
|
Primary tumor site
|
|
Cervical
|
13 (9.7%)
|
|
Upper thorax
|
44 (32.8%)
|
|
Middle thorax
|
60 (44.8%)
|
|
Lower thorax
|
14 (10.4%)
|
|
Mixed
|
3 (2.2%)
|
|
Length of primary tumor
|
|
< 3.5
|
27(20.2%)
|
|
> 3.5
|
104 (77.6%)
|
|
Not available
|
3 (2.2%)
|
|
*T stage
|
|
T1
|
3 (2.2%)
|
|
T2
|
8 (6.0%)
|
|
T3
|
43 (32.1%)
|
|
T4
|
80 (59.7%)
|
|
*N stage
|
|
N0
|
49 (36.6%)
|
|
N1
|
50 (37.3%)
|
|
N2
|
35 (26.1%)
|
|
Concurrent chemotherapy
|
|
No
|
48 (35.8%)
|
|
Yes
|
86 (64.2%)
|
- *TNM staging was determined based on the Clinical non operative treatment of esophageal cancer staging criteria (draft, 2010)
